Loading...
NPI 1528000346 · Mililani Town, HI · Community/Retail Pharmacy
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Longs Drug Stores California LLC is a community/retail pharmacy provider located in Mililani Town, Hawaii. This profile covers 10 Medicare and 12 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Longs Drug Stores California LLC |
| Address | 95 1249 D Meheula Pkwy |
| City | Mililani Town |
| State | HI |
| ZIP | 96789 |
| Taxonomy | Community/Retail Pharmacy |
| NPI Enumerated | June 13, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $356.2K |
| Medicaid | $26.8K |
Service-line profile: LONGS DRUG STORES CALIFORNIA LLC presents the hallmarks of a community/retail pharmacy that is heavily focused on immunizations and COVID testing/distribution. Medicare billing shows large volumes for COVID vaccine 91322 (629 claims, $143 avg paid/claim, $89.9K revenue) and for COVID test distribution K1034 (8.1K claims, $11 avg paid/claim, $88.7K revenue), while multiple influenza and pneumococcal vaccine codes (e.g., 90694, G0008, 90677) also contribute meaningfully to its revenue mix, indicating routine on-site vaccine administration alongside high-volume test provisioning.
Revenue concentration by payer: The provider’s Medicare revenue is highly concentrated in a few service lines — the precomputed top 3 Medicare codes (91322, K1034, 90694) account for 63.9% of its Medicare revenue. On the Medicaid side, the top 3 codes (91322, 90471, 0012A) account for 51.0% of Medicaid revenue, so both payers show reliance on a small set of vaccination and test-related codes.
Payer mix and scale: Medicare accounts for the vast majority of reported program revenue for this NPI, with Total Medicare revenue $356.2K versus Total Medicaid revenue $26.8K, indicating this location operates effectively as Medicare-dominant in scale. That gap suggests core operations and revenue generation are centered on Medicare-covered beneficiaries and services rather than Medicaid populations.
National competitive standing (Medicare): For its top Medicare codes this pharmacy ranks at the very high end of national volume lists (for example 91322 ranks #214 of 29357 providers, 99th percentile; K1034 ranks #365 of 30143, 99th percentile; 90694 ranks #337 of 51679, 99th percentile). Notably, the dataset labels those positions as "typical, unremarkable volume," which implies these high ranks reflect active, high-volume pharmacy practice for common immunization and test distribution services rather than statistical outlier behavior.
State competitive standing (Medicaid): Within Hawaii Medicaid comparisons this location is a modest-to-upper participant rather than a statewide leader. For instance, Medicaid 91322 ranks #12 of 32 in-state (61th percentile; typical, unremarkable volume) and 90471 ranks #69 of 231 in-state (70th percentile; typical, unremarkable volume), indicating consistent but not dominant in-state activity across vaccine administration and related codes.
Tenure and operational stability: The provider’s NPI was enumerated on 2006-06-13 (~20 years ago), indicating long-established billing presence. This tenure supports interpretation that reported service patterns (vaccinations, COVID test distribution, routine pharmacy services) reflect stable, ongoing retail-pharmacy operations rather than a new or transient entrant.
Reimbursement profile across services: There is meaningful variation in avg paid per claim across key codes, with higher per-claim payments for certain vaccines (e.g., Medicare 90677 shows $280 avg paid/claim for $30K revenue) and much lower per-claim amounts for high-volume test distribution (K1034 $11 avg paid/claim). This mix—fewer higher-paid vaccine claims alongside many low-paid test distribution claims—is consistent with a pharmacy model combining clinical vaccine services and bulk COVID-test provisioning.
Limited revenue from ancillary compounding and some admin codes: Some ancillary service lines show negligible revenue in Medicaid (S9430 pharmacy compounding and dispensing services reports $0 revenue) and smaller shares for pneumococcal administration (Medicare G0009 $1.2K revenue). These lines do not materially affect the overall payer revenue profile, which remains concentrated in vaccines and test-related codes.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 630 | $140 | $89.9K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 8,060 | $10 | $88.7K |
| 90694 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is an inactivated, adjuvanted, preservative–free vaccine given as a 0.5 mL… | 670 | $80 | $50.3K |
| G0008 | Administration of influenza virus vaccine | 990 | $30 | $30.5K |
| 90677 | This code represents a vaccine product administered intramuscularly to protect against pneumococcal disease, a bacterial infection. This is a 20–valent vaccine, protecting against 20 strains of the… | 110 | $280 | $30K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 630 | $40 | $27.1K |
| 90662 | This code represents a flu vaccine product that is a split virus type, contains no preservatives, and has enhanced effectiveness due to a higher antigen content. It is administered as an injection… | 300 | $70 | $21.9K |
| 0134A | N/A | 380 | $40 | $16.4K |
| 90732 | The provider intramuscularly or subcutaneously injects pneumococcal polysaccharide vaccine in an individual two years or older. This vaccine provides protection against meningitis and pneumonia that… | 20 | $130 | $2K |
| G0009 | Administration of pneumococcal vaccine | 110 | $10 | $1.2K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 10 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
12 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 60 | $100 | $6.1K |
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 390 | $10 | $3.9K |
| 0012A | N/A | 100 | $40 | $3.7K |
| 0011A | N/A | 100 | $40 | $3.5K |
| 0064A | N/A | 70 | $40 | $2.6K |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 150 | $20 | $2.6K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 60 | $40 | $2.1K |
| 90674 | This code represents a flu vaccine product that protects against four strains of influenza. It is derived from cell cultures, contains no preservatives or antibiotics, and is administered as a 0.5 mL… | 30 | $20 | $740 |
| 0134A | N/A | 20 | $40 | $650 |
| 90661 | This code represents a vaccine product administered into the muscle to protect against the flu virus. This is a trivalent vaccine, meaning it protects against three different strains of influenza.… | 20 | $30 | $530 |
Showing 1–10 of 12
How this provider's Medicaid billing volume and revenue compare to other Hawaii providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Hawaii median
12 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 69 | 230 | 140 | $20 | $16.1K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 12 | 30 | 50 | $110 | $7.7K |
| 0012A | N/A | 37 | 90 | 70 | $30 | $5.6K |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 78 | 180 | 120 | $10 | $4.7K |
| 0011A | N/A | 38 | 90 | 80 | $20 | $4.4K |
| 0064A | N/A | 47 | 100 | 60 | $30 | $3.2K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 25 | 60 | 50 | $30 | $2.8K |
| 0134A | N/A | 29 | 40 | 30 | $30 | $1.5K |
| 90674 | This code represents a flu vaccine product that protects against four strains of influenza. It is derived from cell cultures, contains no preservatives or antibiotics, and is administered as a 0.5 mL… | 39 | 60 | 50 | $20 | $1.3K |
| 90656 | This code represents a preservative–free trivalent influenza vaccine product containing split virus components. It is administered into the muscle in a 0.5 mL dosage. | 52 | 80 | 40 | $10 | $1.2K |
Showing 1–10 of 12
Other providers in the same ZIP code as Longs Drug Stores California LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.